Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loperamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 0.96 |
| ▸ | DRD4 | P21917 | 5/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.96 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.96 |
| ▸ | DRD2 | P14416 | 3/20 | 0.96 |
| ▸ | DRD3 | P35462 | 3/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.96 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.96 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.96 |
| ▸ | HTR2B | P41595 | 2/20 | 0.96 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.96 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.96 |
| ▸ | HRH2 | P25021 | 2/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.96 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loperamide SCHEMBL8409779 | 0.98 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL12387663 | 0.98 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL28530 | 0.98 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL9068543 | 0.97 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL8409268 | 0.97 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL21327979 | 0.97 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL15048 | 0.97 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL2346867 | 0.96 | OPRM1 (0.98) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL5084617 | 0.95 | OPRM1 (0.94) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL12470757 | 0.94 | OPRM1 (0.92) | OPRM1DRD4ADRA2ASLC6A4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12031977-B2 | Ex vivo system for determining multiple drug-drug transporter interactions and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| CN-116672344-A | Application of loperamide hydrochloride in preparation of medicine for treating Salmonella infection | 吉林大学 | 2023-09-01 | — | — | CN | disclosed |
| US-20220273637-A1 | NOVEL PFAR-INHIBITING COMPOUNDS | Institut National de la Santé et de la Recherche Médicale (FR) | 2022-09-01 | — | — | US | disclosed |
| CN-114441663-A | Method for screening protein positive compounds by using solid phase microextraction affinity selection mass spectrum | 中国科学院上海药物研究所 | 2022-05-06 | — | — | CN | disclosed |
| US-20210393645-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2021-12-23 | — | — | US | disclosed |
| US-20210231645-A1 | METHODS AND COMPOSITIONS FOR INVESTIGATING MULTIPLE DRUG-DRUG TRANSPORTER INTERACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-07-29 | — | — | US | disclosed |
| CN-112755072-A | Application of two formulas in preparation of medicine for preventing and treating constipation | 天津中医药大学 | 2021-05-07 | — | — | CN | disclosed |
| CN-110720466-A | Application of loperamide hydrochloride in preparation of bactericide for preventing and treating plant diseases caused by plant pathogenic bacteria | 青岛农业大学 | 2020-01-24 | — | — | CN | disclosed |
| US-20190262353-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2019-08-29 | — | — | US | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070072899-A1 | Method for treating drug and behavioral addictions | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2007-03-29 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-6190691-B1 | ADMINISTERING FORMULATION COMPRISING TUMOR NERCOSIS FACTOR (TNF) PRODUCTION-INHIBITORY AMOUNT OF A COMPOUND SELECTED FROM LOPERAMIDE AND DIPHENOXYLATE TO MAMMAL | ADOLOR CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-5962477-A | USING LOPERAMIDE | ADOLOR CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0937460-A2 | Use of an antidiarrheal for the manufacture of a medicament for the treatment of inflammatory conditions | Adolor Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0757558-A4 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORP (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0757558-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995027510-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | OPRM1 2413/4885DRD4 4415/4885ADRA2A 3369/4885 |
| US-20070072899-A1 | Method for treating drug and behavioral addictions | SLC6A3, OPRD1, DRD2 | OPRM1 12/4885DRD4 9/4885ADRA2A 513/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | OPRM1 265/4885DRD4 1926/4885ADRA2A 317/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | OPRM1 2633/4885DRD4 4301/4885ADRA2A 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.